Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
$44.50
+$0.22 (+0.50%)
Live · 09:09 PM
Margins and capital returns are both well above average: 41.30% operating margin, ROIC at 35.07%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 6.4%, steady but not accelerating. Margins contracted 2.9pp, which offsets some of the top-line progress.
Free cash flow declined 58% versus the prior year, cash generation momentum has weakened. ROIC dropped from 53.65% to 35.07%, capital efficiency is deteriorating.
10.5x earnings, 41.5x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
DKK 327.80B
▲ +6.4% YoY
Net Income (TTM)
DKK 121.96B
▲ +1.4% YoY
Op. Margin
45.30%
▼ -2.9pp YoY
ROIC
35.07%
▼ -18.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
DKK 30.89B
▼ -58.4% YoY
Op. Cash Flow (TTM)
DKK 169.84B
▲ +12.9% YoY
Net Debt
DKK 104.00B
Cash & Equiv.
DKK 26.96B
3Y CAGR: +20.4%
3Y CAGR: -23.3%
Continue Research
At a P/E of 10.5 and a price-to-free-cash-flow of 41.5, Novo Nordisk A S (NVO) trades below a two-stage DCF intrinsic value of about DKK 96.95 per share, so at DKK 44.50 the stock looks undervalued (117.9% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Novo Nordisk A S scores 63/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 4.0%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about DKK 96.95 per share for NVO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around DKK 72.71. At today's DKK 44.50, that puts the stock about 117.9% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Novo Nordisk A S scores 63 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 45.3% operating margin and a 35.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Novo Nordisk A S pays a regular dividend of about DKK 11.64 per share per year (typically in quarterly installments), a yield of roughly 4.0% at the current price. That is a payout ratio of about 42.5% of earnings, so the dividend is well covered. Novo Nordisk A S has grown the dividend at roughly 24.5% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For NVO's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. NVO currently trades below its estimated intrinsic value and scores 63/100 on quality (solid). It also yields about 4.0%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.